The ExAblate system is an image guided, non-invasive, robotic acoustic surgery system integrating magnetic resonance imaging to visualise the tumor and the energy delivery path together with high intensity focused ultrasound beam, delivered with millimeter precision to destroy the cancerous tumor without damaging surrounding tissue.
The ExAblate prostate system has been designed to provide treatments while minimising the side-effects caused by damage to functional areas of the prostate and neurovascular bundles and enable patients to return to normal life within a day or two while maintaining their quality of life.
The use of real-time 3D MR thermometry provides accurate closed-loop monitoring of the treatment outcome and ability to adjust the treatment according to specific patient physiology, in real time.
InSightec president and CEO Kobi Vortman said that unfortunately current treatment alternatives are accompanied by relatively high levels of adverse events which significantly impact the quality of life of prostate cancer patients. The most common are incontinence and impotence.
“Due to the introduction of PSA screening tests, prostate cancer is diagnosed at an earlier age thereby increasing the necessity for a treatment option that minimizes adverse events,” Vortman said.
